GlobeNewswire by notified

REC Silicon - Third quarter 2021 results

Share

Oslo, Norway – October 20, 2021: REC Silicon ASA (REC Silicon) reported third quarter 2021 revenues of USD 36.2 million versus USD 35.6 million in the second quarter of 2021 and an EBITDA loss of USD 3.7 million versus positive USD 7.9 million in the prior quarter.

The Company reported EBITDA contributed by the semiconductor materials segment of USD 1.8 million for the third quarter compared to USD 11.5 million for the second quarter. Second quarter results included other income related to the forgiveness of a loan provided by the US government under the C.A.R.E.S. Act. Excluding this item, EBITDA decreased by USD 5.2 million. This decrease can primarily be attributed to higher electricity prices and lower production caused by the completion of planned maintenance activities and a delayed restart to mitigate high electricity prices.

Silicon gas sales volumes for the third quarter were 728 MT compared to 819 MT during the prior quarter. Total polysilicon sales volumes for the quarter were 397 MT and polysilicon inventories decreased by 101 MT.

In addition, the Company reported USD 13.4 million in profit from discontinued operations during the third quarter due to the settlement of the indemnification loans on October 18, 2021. This transaction also resulted in a decrease in liabilities of USD 13.9 million to USD 10.8 million at September 30, 2021.

REC Silicon reported cash balances of USD 126.3 million on September 30, 2021 compared to USD 123.6 million on June 30, 2021.

“The semiconductor market continues to strengthen from a demand perspective, but our results were unfortunately impacted by high power prices and challenges caused by the global supply chain backlog.

REC Silicon is pleased with the successful resolution of the indemnity loans, which reduced the Company’s debt and removed the remaining uncertainties associated with legacy obligations,“ said Tore Torvund, CEO.

For more information, please see the attached first quarter 2021 report and presentation.

The company will host conference call to present the results at 8:00am CET. Following the presentation, it will be opened for questions from the audience. The presentation will be in English. To join the videoconference, use the following link.
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20211020_1

Audiocast participants need to register to post questions.

For further information, please contact:
James A. May II, Chief Financial Officer
Phone: +1 509 989 1023
Email: james.may@recsilicon.com

Nils O. Kjerstad
IR Contact
Phone: +47 9135 6659
Email: nils.kjerstad@crux.no

About REC Silicon
REC Silicon is a leading producer of advanced silicon materials, delivering high-purity polysilicon and silicon gas to the solar and electronics industries worldwide. We combine over 30 years of experience and proprietary technology with the needs of our customers, with annual production capacity of more than 20,000 MT of polysilicon from our two US-based manufacturing plants. Listed on the Oslo Stock Exchange (ticker: RECSI), the Company is headquartered in Lysaker, Norway.

For more information, go to: www.recsilicon.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Giambattista Valli dazzles Barcelona during the Bridal Night19.4.2024 12:41:00 CEST | Press release

BARCELONA, Spain, April 19, 2024 (GLOBE NEWSWIRE) -- The most exclusive fashion show of the Barcelona Bridal Fashion Week charmed over 450 guests last night who enjoyed a unique show in the historic building of the Llotja de Mar. The Maison Giambattista Valli exclusively celebrated the runway debut of its bridal collection during the Bridal Night, the gala evening of the event organized by Fira de Barcelona with the support of the Catalan Ministry of Business and Labor. In an extraordinary show, Giambattista Valli's 30 creations shone with their own light. It was a culmination of silhouettes, representing a comprehensive exhibition of Mr. Valli’s concept of contemporary bridal dressing, inviting his audience to witness the manifestation of his vision, translated into a presentation that embodies the essence of individuality, sharing a dream and a celebration and love. The fashion show featured ten dresses from the third “Love Collection,” ten iconic silhouettes from the first and secon

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release

WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,

Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse

Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør

Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse

Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er fore­taget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag

HiddenA line styled icon from Orion Icon Library.Eye